MARKET

ADVM

ADVM

Adverum Biotech
NASDAQ
4.170
0.000
0.00%
After Hours: 4.150 -0.02 -0.47% 17:22 12/04 EST
OPEN
4.170
PREV CLOSE
4.170
HIGH
4.240
LOW
4.165
VOLUME
1.38M
TURNOVER
--
52 WEEK HIGH
6.98
52 WEEK LOW
1.780
MARKET CAP
92.06M
P/E (TTM)
-0.4864
1D
5D
1M
3M
1Y
5Y
1D
Adverum Biotechnologies Releases Promising Phase 2 Trial Data
TipRanks · 9h ago
10% Owner Braden Michael Leonard Reports Sale of Adverum Biotechnologies Common Shares
Reuters · 1d ago
Adverum Biotechnologies reminds stockholders to tender their shares
TipRanks · 3d ago
Adverum Urges Shareholders to Accept Eli Lilly Buyout Offering Up to $12.47 Per Share
Benzinga · 3d ago
ADVERUM REMINDS STOCKHOLDERS TO TENDER THEIR SHARES INTO THE OFFER BY LILLY
Reuters · 3d ago
ADVERUM BIOTECHNOLOGIES INC: TENDER OFFER IS SCHEDULED TO EXPIRE ONE MINUTE PAST 11:59 P.M., EASTERN TIME, ON DECEMBER 8, 2025
Reuters · 3d ago
Adverum Urges Shareholders to Accept Lilly Buyout Amid Imminent Liquidation Risk
Reuters · 3d ago
Weekly Report: what happened at ADVM last week (1124-1128)?
Weekly Report · 3d ago
More
About ADVM
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company. It discovers and develops gene therapy product candidates that provide durable efficacy by inducing sustained expression of a therapeutic protein. Its lead product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections. Ixo-vec is being developed for the treatment of patients with wet age-related macular degeneration (wet AMD). Its other partnered programs include BGTF-027 (AAV.7m8-L-opsin), a gene therapy product candidate designed to deliver a functional copy of the OPN1LW gene to the foveal cones of patients suffering from blue cone monochromacy (BCM) via a single IVT injection.

Webull offers Adverum Biotechnologies Inc stock information, including NASDAQ: ADVM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADVM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ADVM stock methods without spending real money on the virtual paper trading platform.